Table 4.
Comparison of patients with or without NSAID hypersensitivity in the Swedish cohort.
| Mastocytosis without NSAID hypersensitivity reaction (n = 156) | Mastocytosis with NSAID hypersensitivity reaction (n = 13) | p-valuea | MMAS without NSAID hypersensitivity reaction (n = 28) | MMAS with NSAID hypersensitivity reaction (n = 5) | p-valuea | |
|---|---|---|---|---|---|---|
| Age at diagnosis, median (range) | 52 (18–83) | 50 (22–66) | 0.503 | 51.5 (28–74) | 55 (36–66) | 0.706 |
| Male gender, n (%) | 72 (46.2) | 5 (38.5) | 0.774 | 15 (53.6) | 1 (20.0) | 0.335 |
| Presence of skin engagement, n (%) | 101 (64.7) | 9 (69.2) | 1.000 | ND | ND | ND |
| Presence of atopy, n (%) | 46 (29.5) (1 NA) | 1 (7.7) (1 NA) | 0.182 | 10 (35.7) | 1 (20.0) (1 NA) | 1.000 |
| Presence of asthma and/or rhinitis, n (%) | 40 (25.6) | 2 (15.4) (2 NA) | 0.732 | 12 (42.9) | 2 (40.0) (1 NA) | 1.000 |
| Total IgE levels (kU/L), median (range) | 14 (1–1600) (2 NA) | 11.5 (4–280) (1 NA) | 0.616 | 25 (6–1100) | 170 (82–250) | 0.004 |
| Baseline tryptase levels (ng/ml), median (range) | 29 (3–650) | 34 (8–530) | 0.981 | 9.0 (3–23) | 17 (4–21) | 0.191 |
| Occurrence of any anaphylaxis, n (%) | 72 (46.2) | 6 (46.2) | 1.000 | 20 (71.4) | 3 (60.0) | 0.627 |
Abbreviations: NA = not analysed. NSAID, non-steroidal anti-inflammatory drug; MMAS, monoclonal mast cell activation syndrome.
a
p-values were calculated using fisher's exact test.
b
p-values were calculated using a 2-tailed Mann-Whitney U-test; bold indicates statistical significance (p < 0.05).